
Cancer in Manitoba

2018 ANNUAL STATISTICAL REPORT



CancerCareManitoba
ActionCancerManitoba

Table of Contents	
Introduction to the Data	2
Manitoba's Cancer Profile	3
Facts & Figures)
Most Common Cancers, 2018	3
Cancer Incidence by Site	4
Manifesto Company Patrick Bandanal	
Manitoba Cancer Rates by Regional	
Health Authority (Incidence)	5
Canada in idan a Canada Batan hu Cita	_
Cancer Incidence—Cases & Rates by Site	6
Tumour Staging by Site	8
Deaths by Underlying Cause in	
Manitoba (Mortality)	10
Appendix 1	
International Classification	
Of Disease for Oncology, 3rd Edition	11

Vision

A world free of cancer

Mission

To reduce and, where possible, eliminate the burden of cancer on the people of Manitoba through exemplary programs of prevention, diagnosis, treatment, rehabilitation, continuing care, research and education.

Introduction to the Data

The Manitoba Cancer Registry is an essential tool for evidence-based, data-driven decision making that has an immense impact on treatment and research. This year's report is based on the following information.

NOTE: All statistics in the body of this report only include Manitoba residents.

Manitoba Cancer Registry data is used for:

- · health care planning and monitoring
- surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- patient care
- quality assurance
- reporting to the Canadian Cancer Registry, the North American Association of Central Cancer Registries and the International Association of Cancer Registries

Information sources include:

- provincial cytology and pathology departments
- admission/separation data from the provincial hospital abstracting system
- Manitoba Provincial Client Registry
- letters and "Report of Malignant Neoplasm Forms" from physicians and other health care providers
- · hospital health records
- correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in those jurisdictions

Incidence data

Incidence refers to the number of new cases of cancer diagnosed in Manitoba every year. Cancer cases referenced were diagnosed in the 2018 calendar year. Incidence is also provided by stage of disease at diagnosis.

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O3), based on Surveillance Epidemiology and End Results (SEER) Groups. See Appendix 1 for the primary site groupings used for incidence.

Mortality data

Mortality information refers to Manitobans who died of cancer in the 2018 calendar year, however, those patients may not have been diagnosed in 2018. The Vital Statistics Agency of Manitoba reported cancer as the leading cause of death in the province. In 2018, there were 2,696 deaths due to invasive cancer (age standardized rate – 198.2 per 100,000). The totals in the summary on page 10 include all cancer deaths occurring in Manitoba.

Rates

Incidence counts and rates are presented in this report. Annual age-standardized rates are per 100,000 population and allow for comparison of cancer rates in different regions with different age structures. Rates are age-standardized (using the direct method) to the 2011 Manitoba population.

Staging data

The Manitoba Cancer Registry has collected cancer stage for all cases of cancer (excluding non-melanoma skin cancer) diagnosed since January 1, 2004. From 2004 to 2017, collection followed the Collaborative Staging method consistent with the American Joint Committee on Cancer (AJCC) 6th and 7th Tumour, Nodes, and Metastases (TNM) editions. For cancer cases diagnosed January 1, 2018 and forward, cancer stage data is being collected following the AJCC 8th edition of the TNM manual.

In this report, stage data is shown for all disease site groups with a cancer incidence of 45 cases per year or more and is represented using pie charts. Stage information, along with frequency of incidence for each of these sites, can also be found in table format on page 8. Due to changes in the staging system, this year we have presented data as early and intermediate stage, and late stage.

Population data

Data are based on Manitoba estimates provided by Manitoba Health.

Additional statistical information is available upon request. Please contact the Manitoba Cancer Registry at:

1-877-787-1272 (toll-free), or CCMBepireg@cancercare.mb.ca

Manitoba's Cancer Profile

Facts & Figures

Manitoba's cancer profile

Cancer is a significant health issue. In 2018, 12,389 Manitobans were diagnosed with cancer:

- 6,973 invasive cancers
- 4,926 in situ (confined to the area of origin)
- **366** unspecified cancers
- 124 benign brain and CNS (central nervous system)

In this same year, **2,696** people died from the disease.

The number of cancer cases in Manitoba is influenced by three factors:

- the age of the population
- the size of the population
- risk factors such as unhealthy living (including smoking, poor diet, inactivity, sun exposure), some environmental carcinogens, genetic predisposition and not being screened.


Most Common Cancer Diagnoses, 2018


Incidence


Male		Female		Total	
SITE	CASES	SITE	CASES	SITE	CASES
Prostate	793	Breast	1024	Breast	1030
Colorectal	474	Lung & bronchus	483	Lung & bronchus	922
Lung & bronchus	439	Colorectal	397	Colorectal	871
Non-Hodgkin Lymphoma	180	Corpus uteri	246	Prostate	793
Kidney	178	Melanoma of the skin	129	Non-Hodgkin Lymphoma	306
Melanoma of the skin	172	Non-Hodgkin Lymphoma	126	Melanoma of the skin	301
Bladder	131	Pancreas	88	Kidney	262
Pancreas	106	Ovary	88	Corpus uteri	246
Stomach	90	Thyroid	86	Pancreas	194
Multiple myeloma	78	Kidney	84	Bladder	169

Cancer Incidence by Site


Invasive cancers only







Manitoba Cancer Rates by Regional Health Authority




2018 All Invasive Cancers Female *Incidence*

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out-of-province residents excluded

2018 All Invasive Cancers Male Incidence

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out-of-province residents excluded



Cancer Incidence - Cases and Rates in Manitoba by Site, 2018

												Ą	ge gro	up									Т	otal Co	ount		ASIR*	
	Cancer Site		00-29	_		30-39			40-49			50-59			60-69	ı _		70-79	_		80+							
	I to	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
	Lip	0	0	0	1	0	1	1	0	1	3	0	3	8	6	14	16	7	23	11	5	16	40	18	58	6.15	2.21	3.96
	Tongue	0	0	0	1	0	1	2	2	4	9	2	11	9	3	12	5	5	10	3	2	5	29	14	43	4.3	1.87	3.03
xux	Major salivary gland	0	0	0	0	0	0	0	0	0	1	0	1	4	1	5	2	3	5	1	1	2	8	5	13	1.14	0.61	0.87
& phar	Floor of mouth	0	0	0	0	0	0	0	0	0	3	1	4	0	0	0	1	0	1	0	1	1	4	2	6	0.6	0.28	0.45
Buccal cavity & pharynx	Gum & other mouth	0	2	2	2	2	4	1	0	1	2	2	4	2	1	3	2	1	3	0	0	0	9	8	17	1.27	1.14	1.2
Bucca	Nasopharynx	0	0	0	0	0	0	3	1	4	3	0	3	5	0	5	0	0	0	1	0	1	12	1	13	1.81	0.16	0.96
	Oropharynx	0	0	0	0	0	0	0	0	0	3	2	5	4	1	5	0	0	0	0	0	0	7	3	10	0.99	0.44	0.71
	Hypopharynx	0	0	0	0	0	0	0	0	0	2	0	2	2	0	2	0	0	0	0	0	0	4	0	4	0.57	0	0.28
	Other buccal cavity & pharynx	0	0	0	0	0	0	1	0	1	8	1	9	8	0	8	2	3	5	1	1	2	20	5	25	2.91	0.64	1.76
	Esophagus	0	0	0	0	0	0	2	0	2	6	1	7	15	4	19	13	7	20	12	5	17	48	17	65	7.36	2.12	4.49
	Stomach	0	0	0	0	1	1	2	1	3	17	1	18	29	14	43	23	7	30	19	13	32	90	37	127	13.63	4.68	8.82
	Small intestine	0	0	0	0	0	0	3	0	3	4	1	5	2	5	7	6	5	11	1	2	3	16	13	29	2.37	1.63	2.01
	Colorectal	5	6	11	9	9	18	23	23	46	88	62	150	132	83	215	132	99	231	85	115	200	474	397	871	71.23	52.23	61.2
و و	Colon excluding rectum	3	5	8	6	4	10	11	13	24	47	36	83	79	59	138	91	79	170	65	96	161	302	292	594	45.83	37.9	41.64
Digestive	Rectum & rectosigmoid	2	1	3	3	5	8	12	10	22	41	26	67	53	24	77	41	20	61	20	19	39	172	105	277	25.4	14.32	19.56
	Anus	0	0	0	0	0	0	0	1	1	1	5	6	1	7	8	4	5	9	1	6	7	7	24	31	1.02	3.17	2.17
	Liver	1	1	2	2	0	2	1	1	2	11	3	14	24	3	27	18	8	26	7	2	9	64	18	82	9.22	2.37	5.6
	Gallbladder	0	0	0	1	0	1	1	0	1	2	2	4	2	6	8	6	3	9	3	4	7	15	15	30	2.27	1.93	2.08
	Pancreas	1	0	1	1	5	6	2	6	8	13	6	19	32	20	52	38	23	61	19	28	47	106	88	194	15.68	11.37	13.41
	Other digestive system	0	1	1	0	0	0	2	1	3	4	5	9	16	9	25	22	8	30	11	11	22	55	35	90	8.18	4.56	6.2
ک	Larynx	0	0	0	0	0	0	2	0	2	4	2	6	15	1	16	8	4	12	9	0	9	38	7	45	5.78	0.91	3.1
Respiratory	Lung & bronchus	0	0	0	3	1	4	7	5	12	44	45	89	130	150	280	158	165	323	97	117	214	439	483	922	65.89	61.16	62.93
Re	Other respiratory system	0	0	0	1	0	1	3	0	3	1	1	2	1	1	2	1	0	1	0	3	3	7	5	12	1.05	0.66	0.89
	Bones & joints	4	3	7	1	0	1	1	2	3	1	0	1	0	0	0	0	0	0	1	0	1	8	5	13	1.24	0.79	0.99
soft art)	Soft tissue (Including heart)	2	1	3	5	0	5	2	1	3	2	1	3	4	1	5	4	3	7	3	4	7	22	11	33	3.27	1.46	2.34
Mesothelial & soft tissue (inc. heart)	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	1	0.13	0	0.06
Mesot	Mesothelioma	0	0	0	0	0	0	1	0	1	1	0	1	2	1	3	5	3	8	6	0	6	15	4	19	2.45	0.48	1.32
	Melanoma of the skin	2	4	6	1	13	14	10	9	19	22	26	48	56	30	86	48	23	71	33	24	57	172	129	301	25.81	17.45	21.06
	Breast	0	4	4	0	44	44	0	122	122	1	195	196	4	300	304	1	210	211	0	149	149	6	1024	1030	0.81	138.65	72.8
	Cervix uteri	0	4	4	0	11	11	0	9	9	0	10	10	0	3	3	0	2	2	0	0	0	0	39	39	0	5.77	0
tal	Corpus uteri	0	2	2	0	8	8	0	24	24	0	50	50	0	91	91	0	48	48	0	23	23	0	246	246	0	33.24	0
Female genital	Uterus, NOS	0	0	0	0	0	0	0	1	1	0	3	3	0	2	2	0	1	1	0	1	1	0	8	8	0	1.13	0
Femã	Ovary	0	2	2	0	4	4	0	10	10	0	19	19	0	23	23	0	20	20	0	10	10	0	88	88	0	12	0
	Other female genital system	0	1	1	0	0	0	0	2	2	0	4	4	0	16	16	0	11	11	0	15	15	0	49	49	0	6.31	0

												Ą	ge gro	up									-	-4-10			AOID*	
	Cancer Site		00-29			30-39			40-49		_	50-5			60-69			70-79			80+			otal Co			ASIR*	
		M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T 070	M	F	T	M	F	T 700	M	F	T
<u>.e</u>	Prostate	0	0	0	0	0	0	9	0	9	103	0	103	299	0	299	270	0	270	112	0	112	793	0	793	114.95	0	0
Male genital	Testis	12	0	12	13	0	13	2	0	2	2	0	2	3	0	3	0	0	0	0	0	0	32	0	32	4.55	0	0
Ma	Penis	0	0	0	0	0	0	0	0	0	2	0	2	0	0	0	4	0	4	7	0	7	13	0	13	2.25	0	0
-	Other male genital system	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	1	0.13	0	0
	Bladder	0	0	0	1	1	2	3	0	3	12	1	13	23	11	34	42	8	50	50	17	67	131	38	169	21.13	4.76	11.88
Urinary	Kidney	4	1	5	7	7	14	20	10	30	49	13	62	49	22	71	31	21	52	18	10	28	178	84	262	26.53	11.31	18.59
] >	Ureter	0	0	0	0	0	0	0	0	0	2	0	2	1	0	1	4	1	5	0	1	1	7	2	9	0.97	0.24	0.61
	Other urinary system	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	6	2	8	1	3	4	9	5	14	1.26	0.61	0.94
	Eye	2	0	2	0	0	0	1	0	1	3	1	4	0	1	1	0	2	2	2	1	3	8	5	13	1.32	0.65	0.96
Brain & other CNS	Brain	7	7	14	4	2	6	3	4	7	6	8	14	15	5	20	17	10	27	5	5	10	57	41	98	8.21	5.69	6.86
Bric	Other nervous system	0	1	1	0	0	0	0	1	1	1	0	1	0	0	0	0	2	2	0	0	0	1	4	5	0.15	0.55	0.36
Endocrine	Thyroid	1	8	9	6	17	23	11	26	37	5	18	23	10	8	18	7	6	13	1	3	4	41	86	127	5.98	12.73	9.35
Endo	Other endocrine	2	3	5	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	2	2	3	5	8	0.42	0.71	0.59
ъ	Hodgkin lymphoma	3	6	9	4	1	5	3	2	5	6	2	8	3	2	5	1	0	1	2	2	4	22	15	37	3.33	2.19	2.73
Lymphoma	Non-Hodgkin lymphoma	3	2	5	12	3	15	10	7	17	27	12	39	52	37	89	51	39	90	25	26	51	180	126	306	26.5	16.3	21.12
Γγ	Multiple myeloma	0	0	0	0	0	0	1	2	3	8	11	19	25	15	40	23	12	35	13	13	26	70	53	123	10.34	6.99	8.49
	Acute lymphocytic leukemia	7	7	14	1	1	2	0	0	0	0	0	0	0	3	3	1	0	1	0	0	0	9	11	20	1.28	1.58	1.43
	Chronic lymphocytic leukemia	0	0	0	0	0	0	0	1	1	7	2	9	16	17	33	19	7	26	9	9	18	51	36	87	7.51	4.58	5.92
nias	Acute myeloid leukemia	1	2	3	3	0	3	1	0	1	2	3	5	7	6	13	10	4	14	7	9	16	31	24	55	4.68	3.13	3.85
Leukemias	Acute monocytic leukemia	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	1	2	3	0.13	0.26	0.21
	Chronic myeloid leukemia	1	0	1	2	2	4	0	1	1	0	2	2	3	1	4	2	5	7	3	1	4	11	12	23	1.68	1.6	1.59
	Other leukemias	0	1	1	0	0	0	4	1	5	0	0	0	1	1	2	2	1	3	1	2	3	8	6	14	1.25	0.81	1.03
	Other ill-defined & unknown	3	1	4	1	1	2	4	2	6	12	12	24	28	24	52	40	27	67	40	52	92	128	119	247	20.11	15.23	17.42
	TOTAL - ALL INVASIVE	61	70	131	82	134	216	142	278	420	503	535	1038	1046	935	1981	1047	821	1868	620	699	1319	3501	3472	6973	521.81	461.32	485.78
	Non-Melanoma skin & in situ skin	6	3	9	23	39	62	80	113	193	228	240	468	524	411	935	661	456	1117	469	446	915	1991	1708	3699	303.15	223.7	257.8
	Breast in situ	0	1	1	0	1	1	0	11	11	0	30	30	1	33	34	0	23	23	0	7	7	1	106	107	0.13	14.56	7.54
	Cervix in situ	0	164	164	0	133	133	0	75	75	0	24	24	0	15	15	0	4	4	0	0	0	0	415	415	0	61.62	0
In situ	Prostate in situ	0	0	0	0	0	0	0	0	0	2	0	2	10	0	10	8	0	8	0	0	0	20	0	20	2.68	0	0
rl la	Bladder in situ	0	0	0	1	0	1	4	1	5	18	3	21	40	8	48	59	15	74	32	10	42	154	37	191	23.09	4.68	13.08
	Colorectal in situ	1	0	1	3	1	4	6	7	13	48	30	78	62	41	103	60	43	103	39	16	55	219	138	357	32.88	18.26	24.79
	Other in situ (Excl. Breast, Skin, Cervix,	1	0	1	0	3	3	0	11	11	13	23	36	16	22	38	17	14	31	8	9	17	55	82	137	8.12	11.38	9.68
<u> </u>	Prostate, Bladder, Colorectal) TOTAL - ALL INVASIVE & IN SITU	69											1697										5941					
-			238	307		311			496		812			1699			1852	1376		1168		2355		5958	11899	891.86	795.53	830.47
-	Brain uncertain & unspecified Neoplasms (Uncertain & unspecified,	1	1	2	0	3	3	0	3	3	0	4	4	3	2	5	3	3	6	1	2	3	8	18	26	1.14	2.54	1.84
	excluding brain)	5	12	17	4	11	15	10	17	27	27	26	53	49	36	85	44	30	74	33	36	69	172	168	340	25.98	22.8	24.04
<u> </u>	Brain & nervous system benign	1	4	5	3	5	8	9	11	20	9	16	25	10	18	28	8	14	22	3	13	16	43	81	124	6.39	11.16	8.91
	ALL CANCERS *Age standardized incidence rate per 100 000	76	255	331	116	330	446	251	527	778	848	931	1779	1761	1521	3282	1907	1423	3330	1205	1238	2443	6164	6225	12389	925.37	832.03	865.27

*Age standardized incidence rate per 100,000 Standard Population: Manitoba 2011

Tumour Staging by Site

Staging on sites with more than 45 cases

LIP

Stage	Frequency	Percent	
Early/Intermediate	56	96.55	
Late	2	3.45	
Total	58	100	



PANCREAS

Stage	Frequency	Percent	
Early/Intermediate	90	46.39	
Late	104	53.61	
Total	194	100	



ESOPHAGUS

Stage	Frequency	Percent	
Early/Intermediate	42	64.62	
Late	23	35.38	
Total	65	100	



OTHER DIGESTIVE SYSTEM

Stage	Frequency	Percent	
Early/Intermediate	77	85.56	
Late	13	14.44	
Total	90	100	



COLORECTAL

Stage	Frequency	Percent	
Early/Intermediate	712	81.75	
Late	159	18.25	
Total	871	100	



LUNG & BRONCHUS

Stage	Frequency	Percent	
Early/Intermediate	528	57.27	
Late	394	42.73	
Total	922	100	



COLON EXCLUDING RECTUM

Stage	Frequency	Percent	
Early/Intermediate	483	81.31	
Late	111	18.69	
Total	594	100	



MELANOMA OF THE SKIN

Stage	Frequency	Percent	
Early/Intermediate	288	95.68	
Late	13	4.32	
Total	301	100	



RECTUM & RECTOSIGMOID

Stage	Frequency	Percent	
Early/Intermediate	229	82.67	
Late	48	17.33	
Total	277	100	



BREAST

Stage	Frequency	Percent	
Early/Intermediate	970	94.17	
Late	60	5.83	
Total	1030	100	



^{*}Early/Intermediate includes non-metastatic and unknown stage cancer diagnoses, while Late stage includes metastatic cancer diagnoses.

^{**}In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries.

CORPUS UTERI

Stage	Frequency	Percent	
Early/Intermediate	228	92.68	
Late	18	7.32	
Total	246	100	



KIDNEY

Stage	Frequency	Percent	
Early/Intermediate	216	82.44	
Late	46	17.56	
Total	262	100	



Stage	Frequency	Percent	
Early/Intermediate	72	81.82	
Late	16	18.18	
Total	88	100	



THYROID

Stage	Frequency	Percent	
Early/Intermediate	124	97.64	
Late	3	2.36	
Total	127	100	



OTHER FEMALE GENITAL SYSTEM

Stage	Frequency	Percent	
Early/Intermediate	45	91.84	
Late	4	8.16	
Total	49	100	



NON-HODGKIN LYMPHOMA

Stage	Frequency	Percent	
Early/Intermediate	186	60.78	
Late	120	39.22	
Total	306	100	



PROSTATE

Stage	Frequency	Percent	
Early/Intermediate	638	80.45	
Late	155	19.55	
Total	793	100	



LIVER

Stage	Frequency	Percent	
Early/Intermediate	62	75.61	
Late	20	24.39	
Total	82	100	



BLADDER

Stage	Frequency	Percent	
Early/Intermediate	143	84.62	
Late	26	15.38	
Total	169	100	



STOMACH

Stage	Frequency	Percent	
Early/Intermediate	82	64.57	
Late	45	35.43	
Total	127	100	



CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

ETHIL HOOT HO ETHIL HOUR					
Stage	Frequency	Percent			
Early/Intermediate	81	93.10			
Late	6	6.90			
Total	87	100			



^{**}Using Lugano and/or RAI stage

^{*}Early/Intermediate includes non-metastatic and unknown stage cancer diagnoses, while Late stage includes metastatic cancer diagnoses.

^{**}In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries.

Deaths by Underlying Cause in Manitoba¹

(Rate per 100,000)

	2018			2017		2016			
CAUSES OF DEATH	Number	Rate per MB Health Population	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*
Accidents (V01-X59, Y85-Y86)	379	27.9	28	422	31.1	31.5	530	39.6	40.2
Cancer (C00 - C97)	2,696	198.2	199.4	2,456	181	183.5	2,801	209.1	212.5
Cerebrovascular Disease (I60 - I69)	526	38.7	38.9	561	41.3	41.9	604	45.1	45.8
Diabetes (E10 - E14)	315	23.2	23.3	276	20.3	20.6	319	23.8	24.2
Diseases of the heart (100 - 109, 111, 113, 120 - 125, 126 - 151)	1,951	143.4	144.3	1,883	138.8	140.7	2,166	161.7	164.3
Pneumonia (J12 - J18)	187	13.7	13.8	184	13.6	13.8	237	17.7	18
Intentional Self-Harm (X60 - X84, Y890)	219	16.1	16.2	166	12.2	12.4	193	14.4	14.6

Reference

¹Vital Statistics Agency, 2018/19 Annual Report. Government of Manitoba; 2019. [cited March 06, 2023].

http://vitalstats.gov.mb.ca/pdf/2019_vs_annual_report_en.pdf

Appendix 1

INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY

3rd Edition

PRIMARY SITE	SITE/ CELL TYPE
Buccal cavity and pharynx	C00:C14
Lip	C000:C009
Tongue	C019:C029
Major salivary gland	CO79:CO89
Floor of mouth	C040:C049
Gum & other mouth	C030:C039, C050:C059, C060:C069
Nasopharynx	C110:C119
Oropharynx	C100:C109
Hypopharynx	C129, C130:C139
Other buccal cavity & pharynx	C090:C099, C140, C142:C148
Digestive system	C15:C26
Esophagus	C150:C159
Stomach	C160:C169
Small intestine	C170:C179
Colon excluding rectum	C180:C189, C260
Rectum & Rectosigmoid	C199, C209
Anus	C210:C212, C218
Liver	C220
Gallbladder	C239
Pancreas	C250:C259
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269
	C488
Respiratory system	C30:C39
Larynx	C320:C329
Lung & bronchus	C340:C349
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383, C388, C390:C399
Bones & joints	C400:C419
Soft tissue (including heart)	C380, C470:C479, C490:C499
Mesothelioma	9050:9055
Kaposi sarcoma	9140
Skin	C44
Melanomas of the skin	C440:C449 (8720:8790)
Other skin	C440:C449
Breast	C500:C509
Female genital system	C51:C58
Cervix uteri	C530:C539
Corpus uteri	C540:C549
Uterus, NOS	C559
Ovary	C569
Other female genital system	C529, C510:C519, C570:C589

PRIMARY SITE	SITE/ CELL TYPE
Male genital system	C60:C63
Prostate	C619
Testis	C620:C629
Penis	C600:C609
Other male genital system	C630:C639
Urinary system	C64:C68
Bladder (incl. <i>in situ</i>)	C670:C679
Kidney and renal pelvis	C649, C659
Ureter	C669
Other urinary system	C680:C689
Eye	C690:C699
Brain & other nervous system	C70:C72
Brain	C710:C719
Other nervous system	C710:C719 (953), C700:C709. C720:C729
Endocrine	C73:C75
Thyroid	C739
Other endocrine	C379, C740:C749, C750:C759
Lymphomas	
Hodgkin lymphoma	9650-9667
Non-Hodgkin lymphoma	9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737, 9738
	9811-9818 (except C420, C421, C424) 9823 (except C420, C421, C424) 9827 (except C420, C421, C424) 9837 (except C420, C421, C424)
Myeloma	9731-9732, 9734
Leukemias	C42
Acute lymphocytic	9826, 9835-9836 9811-9818 (only C421) 9837 (only C421)
Chronic lymphocytic	9823 (only C421, if SLL C77)
Acute myeloid	9840, 9861, 9865-9867, 9869, 9871-9874, 9895- 9897, 9898, 9910-9911, 9920,
Acute monocytic	9891
Chronic myeloid	9863, 9875-9876, 9945-9946
Other	9733, 9742, 9800, 9801, 9805-9809, 9820, 9831- 9834, 9860, 9870, 9930, 9931, 9940, 9948, 9963, 9964 9827 (only C421)
Other, ill-defined, & unknown	9740-9741, 9750-9769, 9950, 9960-9962, 9965- 9967, 9970-9971, 9975, 9980, 9982-9987, 9989, 9991-9992 C420-C424 (except 9050-9055, 9140, 9590-9992) C760-C768 (except 9050-9055, 9140, 9590-9992) C770-C779 (except 9050-9055, 9140, 9590-9992) C809 (except 9050-9055, 9140, 9590-9992)

CONTACT DETAILS

Epidemiology and Cancer Registry CancerCare Manitoba 675 McDermot Ave. Winnipeg, MB R3E oV9 Main line: (204) 787-2174

Email: CCMBepireg@cancercare.mb.ca

TO CITE THIS REPORT

Department of Epidemiology and Cancer Registry, CancerCare Manitoba. "Cancer in Manitoba, 2018 Annual Statistical Report."

Find the Department of Epidemiology and Cancer Registry and data request guidelines online under the Research tab at www.cancercare.mb.ca

